GlassScriptPhysician profile
Laura Gerla
NPI 1932637121
$4,018.59
in general payments reported to CMS, 2019-2025
32 companies · $840 in 2025
The $840 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.24 · 2022: $239 · 2023: $1,507 · 2024: $1,418 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,764.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.36 | 2022-2025 | |
| Lilly USA, LLC | $486.17 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $289.36 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $222.15 | 2023-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.75 | 2023-2025 | Xifaxan |
| Pfizer INC. | $172.24 | 2023-2025 | |
| Medtronic, INC. | $148.26 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Otsuka America Pharmaceutical, INC. | $136.97 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $131.47 | 2022-2023 | |
| Melinta Therapeutics, LLC | $120.87 | 2021-2022 | |
| Averitas Pharma INC. | $118.76 | 2023 | Qutenza |
| Exact Sciences Corporation | $109.68 | 2023-2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $80.47 | 2024-2025 | Xyosted |
| Astellas Pharma US INC | $78.32 | 2023-2024 | Veozah |
| Abbott Laboratories | $77.09 | 2023-2025 | Proclaim, Freestyle Libre 3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $69.21 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $68.60 | 2022-2025 | Repatha, Otezla, Repatha |
| Paratek Pharmaceuticals, INC. | $67.04 | 2024-2025 | Nuzyra |
| Tolmar, INC. | $62.53 | 2024-2025 | Jatenzo |
| Inspire Medical Systems, INC. | $59.20 | 2023-2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.87 | 2023 | Jardiance |
| Esperion Therapeutics, INC. | $42.06 | 2023-2024 | Nexletol |
| Glaxosmithkline, LLC. | $41.61 | 2023-2024 | Trelegy Ellipta |
| Optinose US, INC. | $38.53 | 2024-2025 | |
| Hologic Sales and Service, LLC | $31.22 | 2025 | Aptima |
| Currax Pharmaceuticals LLC | $25.58 | 2023 | Contrave, Nexlizet, Nexletol |
| Idorsia Pharmaceuticals US INC | $24.79 | 2022 | |
| Noven Therapeutics, LLC | $24.43 | 2024 | Xelstrym |
| Acella Pharmaceuticals, LLC | $21.11 | 2024 | NP Thyroid 60 |
| Lundbeck LLC | $19.73 | 2024 | Rexulti |
| Halozyme INC | $16.16 | 2023 | |
| Impel Pharmaceuticals INC. | $13.00 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Gerla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.